Kenya Investigates Human Infection Studies

Researchers in Kilifi, Kenya, are conducting human infection studies to accelerate the development of a Shigella vaccine. The studies involve deliberately infecting healthy volunteers with the bacterium under strict medical supervision.

The process aims to evaluate vaccine candidates and understand immune responses to the disease, which remains a significant public health concern, particularly in sub-Saharan Africa.

The Shigella Vaccine Development Process

Human infection studies involve the deliberate infection of healthy adult volunteers with a pathogen. Volunteers undergo thorough screening and health confirmation before being infected in a controlled setting. Researchers closely monitor participants, tracking symptoms and collecting laboratory samples, and initiating treatment promptly upon the appearance of clinical signs. The primary objective is to test the efficacy of vaccine candidates and, if successful, progress to larger trials.

Shigella as a Public Health Threat

Diarrhoea caused by Shigella is a major public health threat, especially in sub-Saharan Africa. It is a leading cause of childhood illness and death in coastal Kenya. Currently, no licensed Shigella vaccine is routinely used globally. Human infection studies are valuable in endemic settings where prior exposure and immunity vary.

Addressing Ethical Concerns and Building Trust

Recruiting volunteers for deliberate infection requires extensive community engagement. Researchers acknowledge the initial fear and apprehension participants may have, emphasizing that studies are conducted only for diseases with established treatments. Participants receive prompt treatment as soon as symptoms develop and are discharged only after full recovery. The program has conducted human infection studies for over a decade without participant deaths or severe complications directly linked to the research. Volunteers receive medical follow-up for up to 18 months post-discharge.

Human infection studies undergo rigorous ethical and regulatory review, including input from community members before protocols are submitted. Emergency systems, including resuscitation facilities and ambulances, are readily available.

Local Research with Global Implications

The program initially began conducting human infection studies in Nairobi in 2013 and later expanded to Kilifi, recruiting volunteers from the local demographic surveillance area. Generating evidence in African populations is considered crucial for diseases disproportionately affecting the continent. A successful vaccine developed through these studies could significantly reduce childhood mortality in Kilifi, where Shigella contributes to a substantial number of hospitalizations and deaths.

Community Engagement and Transparency

Researchers emphasize inclusive consultation, clear messaging, sustained dialogue, and proactive media engagement to counter misinformation and build public trust in ethically sensitive research. These strategies were highlighted during a presentation at the 16th KASH Conference.